By Fineline Cube 
China-based Yangtze River Pharmaceutical Group announced on July 25, 2025, that its Class 1 innovative drug, Tadalafil Hydrochloride Tablets (Trade Name: Taituotuo), has received marketing approval from China’s National Medical Products Administration (NMPA). The drug is indicated for the treatment of erectile dysfunction (ED).
Drug Mechanism
Tadalafil Hydrochloride Tablets are a phosphodiesterase 5 (PDE5) inhibitor. They work by dilating cavernous blood vessels to improve penile erectile function. This approval marks a significant milestone for Yangtze River Pharmaceutical, offering patients with ED a new treatment option.
Innovative Achievement
This approval highlights Yangtze River Pharmaceutical’s commitment to developing innovative solutions in the field of men’s health. Taituotuo represents an independently developed achievement by the company, further expanding its portfolio of pharmaceutical products.-Fineline Info & Tech